London, UK, Boston, MA, 9 November 2025 George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term efficacy and safety data from a 52-week open-label extension of its pivotal Phase 3 study in treatment-naïve patients with hypertension. In this 52-week follow-up period of 50 subjects, treatment with GMRx2 (US tradename WIDAPLIKTM), demonstrated sustained blood pressure (BP) control out to one year, with good tolerability and low treatment discontinuation.
Tag: biopharmaceutical
DNA Manufacturing Market Size to Hit USD 20.28 Billion by 2032, Fueled by Gene Therapy and Synthetic Biology Growth – SNS Insider
As per SNS Insider Research, The DNA Manufacturing Market growth is driven by plasmid DNA demand, biopharma innovation, and advancements in DNA-based vaccine production. As per SNS Insider Research, The DNA Manufacturing Market growth is driven by plasmid DNA demand, biopharma innovation, and advancements in DNA-based vaccine production.